BCL3 Antibody

中文名稱：

BCL3兔多克隆抗體
貨號(hào)：

CSB-PA002623LA01HU
規(guī)格：

￥440
圖片：
Western Blot
Positive WB detected in: Hela whole cell lysate, Raji whole cell lysate, 293T whole cell lysate, 293 whole cell lysate, A549 whole cell lysate
All lanes: BCL3 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 55 kDa
Observed band size: 55 kDa

IHC image of CSB-PA002623LA01HU diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Secondary antibody only control: uses 1% BSA instead of primary antibody

Immunofluorescence staining of Hela cell with CSB-PA002623LA01HU at 1:30, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Immunofluorescence staining of Hela cell with 5% goat serum, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Immunofluorescence staining of A549 cell with CSB-PA002623LA01HU at 1:30, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Immunofluorescence staining of A549 cell with 5% goat serum, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) BCL3 Polyclonal antibody
Uniprot No.：

P20749
基因名：

BCL3
別名：

B cell CLL/lymphoma 3 antibody; B cell leukemia/lymphoma 3 antibody; B cell lymphoma 3 encoded protein antibody; B-cell lymphoma 3 protein antibody; Bcl 3 antibody; BCL 4 antibody; BCL-3 antibody; Bcl3 antibody; BCL3_HUMAN antibody; BCL4 antibody; Chronic lymphatic leukemia protein antibody; D19S37 antibody; Protein Bcl 3 antibody; Proto-oncogene BCL3 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human, mouse, Rat
免疫原：

Synthesized peptide derived from human protein
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，BCL3 Antibody (CSB-PA002623LA01HU)，的標(biāo)記方式是Non-conjugated。對于BCL3 Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號(hào)	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA002623LB01HU	BCL3 Antibody, HRP conjugated	ELISA
FITC	CSB-PA002623LC01HU	BCL3 Antibody, FITC conjugated
Biotin	CSB-PA002623LD01HU	BCL3 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide and 50% glycerol pH 7.3
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Contributes to the regulation of transcriptional activation of NF-kappa-B target genes. In the cytoplasm, inhibits the nuclear translocation of the NF-kappa-B p50 subunit. In the nucleus, acts as transcriptional activator that promotes transcription of NF-kappa-B target genes. Contributes to the regulation of cell proliferation.
基因功能參考文獻(xiàn)：
1. Bcl3 overexpression could be a surrogate biomarker for NF-kappaB activation in Barrett's epithelial cells leading to deregulation of NF-kappaB-inducible gene expression, inferring resistance to apoptosis through the activation of anti-apoptotic genes such as Survivin. PMID: 29473241
2. Data show that B-cell CLL-lymphoma 3 (Bcl-3) expression levels in colonic T cells correlate with disease manifestation in patients with inflammatory bowel disease. PMID: 28452361
3. Bcl-3 participates in the IL-22-induced expression of STAT3-dependent late-response genes, and the combination of IL-22 and IL-17-induced psoriasis-related gene expression. PMID: 28901004
4. B-cell leukemia protein 3 (Bcl3) expressed in response to cytokine TWEAK stimulation (experimental kidney injury) decreases TWEAK-induced inflammatory and lethal responses. PMID: 28684863
5. Four gene signature (PTEN, PIK3C2A, ITPA and BCL3) is an independent prognostic factors of both overall survival and disease-free survival in clear-cell renal-cell carcinoma. PMID: 27779101
6. Akt2, Erk2, and IKK1/2 phosphorylate Bcl3, converting Bcl3 into a transcriptional coregulator by facilitating its recruitment to DNA. PMID: 28689659
7. Bcl-3 knockdown enhanced the degradation of Smad3 but not Smad2 following TGFbeta treatment. PMID: 27906182
8. We have shown for the first time that BCL-3 promotes the growth of colorectal cancer cells through activation of the AKT pathway, increasing tumour cell yield both in vitro and in vivo. PMID: 26033966
9. BCL3 serves as an oncogene in glioma by modulating proliferation, cell cycle progression and apoptosis, and its oncogenic effects are mediated by the STAT3 signaling pathway. PMID: 27748795
10. miR-19b silencing promoted cell proliferation and cell cycle progression in gastric cancer cells and BCL3 was identified as a direct target of miR-19b PMID: 27572553
11. Study confirmed that BCL-3 is overexpressed in hepatocellular carcinoma (HCC) tissues and correlated with adverse clinicopathological features and poorer prognosis. BCL-3 can promote the growth of HCC cells by promoting cell viability, proliferation and cell cycle progression through regulation of CCND1 expression. PMID: 26882953
12. Bcl3 reduces the inflammatory response in pancreas/biliary tissue by blocking ubiquitination and proteasome-mediated degradation of nuclear factor-kappaB p50 homodimers. PMID: 26526716
13. Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients PMID: 26122346
14. Subcellular localization of Bcl-3 could be a potential-early diagnostic marker in colon cancer. PMID: 25929479
15. Bcl-3 is involved in the development of Tfh cells and the pathogenesis of RA, presumably by inducing IL-21 production. PMID: 26138292
16. Suggest the involvement of BCL3 in cardiovascular disease, which could be partly mediated through the influence on metabolic phenotypes. PMID: 25374339
17. These findings suggest that the two LMP1 signaling domains modulate their combined activity and that the bcl3 transcription factor is likely responsible for some of the unique effects of CTAR1 domain on cellular expression. PMID: 25873381
18. DC-SIGN directs adaptive T helper cell type-2immunity to fucose-expressing pathogens via an IKKepsilon-CYLD-dependent signalling pathway leading to Bcl3 activation. PMID: 24867235
19. data show that BCL-3 makes extensive contacts with p50 homodimers and in particular with ankyrin repeats (ANK) 1, 6, and 7, and the N-terminal region of Bcl-3. PMID: 25922067
20. a delayed (incoherent) feed-forward loop together with differential rates of TNFA (fast) and BCL3 (slow) mRNA turnover provide robust, pulsatile expression of TNFalpha PMID: 24130828
21. Bcl-3 plays a critical role in stabilizing c-Myc protein via ERK activation. PMID: 23794716
22. It protects cells from apoptosis by regulationg apoptotic pathways. PMID: 23494744
23. Bcl-3 may contribute to the adult T cell leukemia development through the positive regulation of cell growth, DNA stabilization and NF-kappaB activation. PMID: 23534762
24. elevated expression in patients with Crohn's disease and ulcerative colitis PMID: 23607276
25. RHBDD1 could inhibit cell apoptosis by activating and upregulating c-Jun and its downstream target, Bcl-3 PMID: 23669365
26. using Bcl-3 knockdown in prostate cancer cells, identified the inhibitor of DNA-binding (Id) family of helix-loop-helix proteins as potential Bcl-3-regulated genes PMID: 22580608
27. Carriers of BCL3 allele rs7257231T had longer posterior cranial bases than noncarriers, and in the familial-based association test showed the statistically strongest relationship to phenotype. PMID: 23115114
28. These results indicate for the first time a cell-autonomous disease-modifying role for Bcl3 in vivo, affecting metastatic disease progression rather than primary tumor growth. PMID: 23149915
29. acute alcohol treatment induces molecular signatures of TLR4/LPS tolerance through the induction of Bcl-3 PMID: 22782967
30. a novel mechanism for regulatory control of CTCF in UV stress-induced human corneal epithelial cells, which requires activation and formation of Bcl-3/p50 complex through a noncanonical NF-kappaB pathway PMID: 21912613
31. inhibitory effect on OC cell growth was mediated by miR-125b inhibition of the translation of an mRNA encoding a proto-oncogene, BCL3 PMID: 20658525
32. We validated STAT3 as a bona fide target of BCL3 in a cervical cancer cell line by additional interference RNA and in silico analyses of previously reported lymphoma patients. PMID: 20974051
33. found that depleting Bcl-3 protein using shRNAs induce a decrease of proliferation and clonogenic survival associated with the induction of multinucleation and increased ploidy PMID: 20731879
34. Genetic variations of UBE2L3 and BCL3 are potential new risk genes for Crohn's disease. PMID: 20601676
35. this study reveals a novel combinatorial role for Bcl3 and CtBP1, providing an explanation for the acquisition of resistance to apoptosis in cancer cells, which is a major requirement for cancer development. PMID: 20800578
36. Data defined a unique motif of BCL-3 that is needed for its recruitment to the proteasome and identified PSMB1 as a key protein required for the proteasome-mediated degradation of a nuclear and oncogenic IkappaB protein. PMID: 20558726
37. Biochemical purification of interacting partners of BCL-3 led to the identification of CtBP as a molecule required for the ability of BCL-3 to repress gene transcription. PMID: 20547759
38. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer PMID: 20414006
39. Human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells. PMID: 20471052
40. Bcl-3 interacts with the pleckstrin homology domain and the phosphotyrosine binding domain of IRS-3, and that IRS-3 interacts with the ankyrin repeat domain of Bcl-3. PMID: 20226764
41. JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network hasa role in basal cancer cell survival PMID: 19806201
42. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. PMID: 12456498
43. BCL3 is downregulated by p53 to repress cyclin D1 and has a role in regulation of cell cycle progression PMID: 12808109
44. The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies. PMID: 15105810
45. Supported by IL-12 signals, Bcl-3 enhances survival and clonal expansion of transgenic OT-1 CD8 T cells. PMID: 15634875
46. Bcl-3 might participate in oncogenic pathways involving Lck PMID: 16099425
47. (p52)2/Bcl-3P ternary complex, which is specifically induced in CD30-stimulated anaplasstic larage cell lymphoma, can modulate expression of apoptosis-related genes regulated by NF-kappaB. PMID: 16108830
48. elevated Bcl-3 expression has an important function in classical Hodgkin lymphoma and peripheral T-cell non-Hodgkin lymphoma, in particular anaplastic large-cell lymphomas PMID: 16123212
49. overexpression of BCL3 increases apoptosis, whereas BCL3-specific siRNA does not affect the viability of INA-6 cells suggesting that BCL3 is not essential for the survival of these cells PMID: 16732314
50. study indicates that BCL3 translocations are not restricted to B-cell chronic lymphocytic leukemia but present in a heterogeneous group of B-cell malignancies PMID: 17495977
顯示更多

收起更多
相關(guān)疾?。?/div>
A chromosomal aberration involving BCL3 may be a cause of B-cell chronic lymphocytic leukemia (B-CLL). Translocation t(14;19)(q32;q13.1) with immunoglobulin gene regions.
亞細(xì)胞定位：

Nucleus. Cytoplasm. Cytoplasm, perinuclear region.
數(shù)據(jù)庫鏈接：

HGNC: 998

OMIM: 109560

KEGG: hsa:602

STRING: 9606.ENSP00000164227

UniGene: Hs.31210

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human